<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03298334</url>
  </required_header>
  <id_info>
    <org_study_id>17-2694</org_study_id>
    <nct_id>NCT03298334</nct_id>
  </id_info>
  <brief_title>Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.</brief_title>
  <official_title>Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonates delivered by scheduled Cesarean Section will be randomized to receive vaginal&#xD;
      seeding (exposing the infant to Mother's vaginal flora) or sham. Infants will be followed for&#xD;
      three years to examine health outcomes including microbiome development, immune development,&#xD;
      metabolic outcomes, and any adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cesarean section (CS) delivery is a common surgical procedure intended to increase the&#xD;
      chances of successful delivery and to protect the health of the mother and baby. Yet this&#xD;
      intervention is overused and has been associated with higher risk of immune and metabolic&#xD;
      disorders in the offspring. It is hypothesized that these associations are due to&#xD;
      CS-delivered newborns not receiving the full inoculum of maternal microbes at birth.&#xD;
&#xD;
      While restoring labor is not possible, restoring the microbes that colonize infants during&#xD;
      birth through exposure to vaginal flora, is feasible, and has been shown in a small pilot&#xD;
      study, to normalize the microbiota of the intestine, skin and mouth during the first month of&#xD;
      life.&#xD;
&#xD;
      The investigators hypothesize that the restoration of the vaginal microbiota to the infant at&#xD;
      birth will restore the infant microbiome and decrease the risk of obesity and other&#xD;
      immune-mediated diseases linked with CS. The investigators aim to test this hypothesis in a&#xD;
      randomized controlled trial by first examining the effect of vaginal seeding, in CS-delivered&#xD;
      newborns, on the gut microbiota composition, structure and function (Phase I of study; first&#xD;
      50 infants) and then on the BMI z score and other immune-mediated outcomes (Phase II of&#xD;
      study; 600 infants).&#xD;
&#xD;
      Methods: CS-delivered neonates will be randomized to either an experimental arm with exposure&#xD;
      to the maternal vaginal microbiota at birth, or a control arm with no exposure. Feces, skin&#xD;
      and vaginal swabs will be collected for microbiome analysis. The investigators will obtain&#xD;
      clinical information from in-person visits, surveys and the electronic health record.&#xD;
&#xD;
      Implications: this randomized controlled clinical study will provide evidence of whether the&#xD;
      &quot;vaginal seeding&quot; procedure can safely transfer microbes from mom-to-baby, and whether these&#xD;
      microbes are beneficial for the metabolic and immune health of the child.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adiposity</measure>
    <time_frame>2 years</time_frame>
    <description>E.g. Body mass index z-score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Monitoring for adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>3 years</time_frame>
    <description>Intestinal microbiota development over the first three years of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune and inflammatory regulation</measure>
    <time_frame>3 years</time_frame>
    <description>E.g. Monitoring for immune and inflammatory mediated conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cesarean Delivery Affecting Newborn</condition>
  <condition>Obesity, Childhood</condition>
  <condition>Intestinal Microbiome</condition>
  <arm_group>
    <arm_group_label>Receives Vaginal Seeding</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Vaginal Seeding</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaginal Seeding</intervention_name>
    <description>A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.</description>
    <arm_group_label>Receives Vaginal Seeding</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Vaginal Seeding</intervention_name>
    <description>A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.</description>
    <arm_group_label>No Vaginal Seeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Mother:&#xD;
&#xD;
          -  Scheduled for cesarean delivery at &gt;/= 37 weeks&#xD;
&#xD;
          -  Pregnant with single fetus, in good general health, age 18 years or older&#xD;
&#xD;
          -  Negative maternal testing for infections transmitted through vaginal and/or other body&#xD;
             fluids performed as standard of care tests in early pregnancy&#xD;
&#xD;
          -  Negative testing for GBS at 35-37 weeks gestation&#xD;
&#xD;
          -  Vaginal pH &lt; 4.5 indicative of Lactobacillus-dominated vaginal microbiota&#xD;
&#xD;
          -  No maternal or fetal complications that may inhibit the ability to perform microbiome&#xD;
             restoration per protocol&#xD;
&#xD;
          -  English or Spanish speaking&#xD;
&#xD;
          -  Negative maternal testing for Gonorrhea, Chlamydia, Hepatitis B, Hepatitis C,&#xD;
             Syphilis, and HIV at 35 weeks gestation or later&#xD;
&#xD;
          -  Women aged 21-29 years should have a normal Pap test within 3 years&#xD;
&#xD;
          -  Women aged 30-65 years should have a normal Pap test and an HPV test (co-testing)&#xD;
             within 5 years or a normal Pap test alone within 3 years&#xD;
&#xD;
        Inclusion Criteria for Infant:&#xD;
&#xD;
        -Infant condition after delivery requires no more than standard neonatal resuscitation* or&#xD;
        is otherwise medically unable to receive the full VMT procedure&#xD;
&#xD;
        *Standard neonatal resuscitation may include: tactile stimulation, bulb suction, oxygen&#xD;
        without positive pressure and drying&#xD;
&#xD;
        Exclusion Criteria for Mother:&#xD;
&#xD;
          -  Delivery at a hospital other than Inova Health System&#xD;
&#xD;
          -  Systemic medication for immunosuppression including biological agent within three&#xD;
             months of cesarean delivery (exclusive of medications used for non-immunosuppressive&#xD;
             purposes - e.g. betamethasone for fetal lung maturation)&#xD;
&#xD;
          -  CD scheduled for active infection that would have interfered with vaginal delivery&#xD;
             such as genital herpetic lesions&#xD;
&#xD;
          -  Onset of labor or rupture of membranes prior to scheduled CD&#xD;
&#xD;
          -  Bacterial vaginosis&#xD;
&#xD;
          -  Symptomatic urinary tract infection&#xD;
&#xD;
          -  Antibiotic therapy within 30 days of cesarean delivery (exclusive of medication use&#xD;
             for prophylaxis at the time of surgery)&#xD;
&#xD;
          -  Symptoms on admission suggesting Chorioamnionitis, e.g. maternal fever, fundal&#xD;
             tenderness&#xD;
&#xD;
          -  Symptoms on delivery admission of possible vaginal infection such as genital herpetic&#xD;
             lesions&#xD;
&#xD;
          -  History positive testing for GBS infection&#xD;
&#xD;
          -  History of a child with a diagnosis of GBS sepsis&#xD;
&#xD;
          -  Pregnancy a result of donor egg or surrogacy&#xD;
&#xD;
          -  Preexisting history of Type I or Type II Diabetes&#xD;
&#xD;
          -  Maternal history of documented genital HPV infection, positive HPV testing or genital&#xD;
             warts on physician examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchitra Hourigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noel Mueller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Gloria Dominguez Bello, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Appel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suchitra Hourigan, MD</last_name>
    <phone>703-776-8199</phone>
    <email>suchitra.hourigan@inova.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shira Levy</last_name>
    <phone>703-776-8199</phone>
    <email>shira.levy@inova.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inova Health System</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suchitra Hourigan, MD</last_name>
      <phone>703-776-8199</phone>
      <email>suchitra.hourigan@inova.org</email>
    </contact>
    <investigator>
      <last_name>Ankit Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, Cox LM, Amir A, Gonzalez A, Bokulich NA, Song SJ, Hoashi M, Rivera-Vinas JI, Mendez K, Knight R, Clemente JC. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med. 2016 Mar;22(3):250-3. doi: 10.1038/nm.4039. Epub 2016 Feb 1.</citation>
    <PMID>26828196</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inova Health Care Services</investigator_affiliation>
    <investigator_full_name>Suchitra Hourigan</investigator_full_name>
    <investigator_title>Vice Chair of Research, Inova Children's Hospital. Pediatric Gastroenterologist.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be shared with co-principal investigators (Maria Glora Dominguz Bello at Rutgers University and Noel Mueller at Johns Hopkins School of Medicine).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

